Jerry Cade, MD
Family Medicine · Las Vegas, NVNPI 1346311354
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $117,515 of the $179,921 with a category attached, or 65.3%. 8 manufacturers reported payments, led by Gilead at 53.0% of the total. Reporting peaked in 2023 at $38,601 and has fallen 57.5% since, to $16,415 in 2025. Among family medicine clinicians in NV with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 361 payments — averaging $498.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$95K
- Viiv Healthcare Company$51K
- Merck$30K
- Roche Diagnostics Corporation$4K
- AbbVie$74
- Otsuka America Pharmaceutical, Inc.$17
- plus $28 from 2 others
Across 31 payments — averaging $6488.28 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Viiv Healthcare Company$192K
- Merck$9K
What the payments were for
- Consulting fees$39,17522%
- Speaking & faculty fees$117,51565%
- Travel & lodging$14,9628%
- Food & beverage$8,2695%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 127 | $95,302 |
| Viiv Healthcare Company | 164 | $50,759 |
| Merck | 59 | $29,967 |
| Roche Diagnostics Corporation | 5 | $3,773 |
| AbbVie | 3 | $74 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Napo Pharmaceuticals Inc | 1 | $17 |
| Dynasplint Systems Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$179,921 in reported general payments places this provider in the 95th percentile of 902 family medicine providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 194 | $772,252 |
| DovatoDolutegravir Sodium/Lamivudine | 29 | $81,164 |
| TivicayDolutegravir Sodium | 24 | $62,861 |
| DescovyEmtricitabine/Tenofov Alafenam | 23 | $49,825 |
| OzempicSemaglutide | 13 | $14,291 |
| Potassium Chloride | 15 | $286 |
| Tamsulosin Hcl | 26 | $252 |
| Testosterone Cypionate | 11 | $248 |
| Lisinopril | 18 | $198 |
| Tramadol Hcl | 29 | $180 |
| Metoprolol Tartrate | 18 | $164 |
| Ibuprofen | 16 | $164 |
| Atorvastatin Calcium | 32 | $139 |
| Metformin Hcl | 15 | $129 |
| Losartan Potassium | 15 | $129 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy | $95,302 | $822,077217 claims |
| Viiv Healthcare CompanyDovato, Tivicay | $50,759 | $144,02553 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 902 family medicine providers in Nevada.
Other family medicine in Las Vegas
- Naz WahabLas Vegas$563K
- Nilesh GokalLas Vegas$75K
- Warren MagnusLas Vegas$70K
- Kimberly AdamsLas Vegas$51K
- Mandeep GillLas Vegas$24K
- Francis JimenezLas Vegas$20K
- Ryan HuangLas Vegas$18K
- Ma Francesca ChamianLas Vegas$17K
- Leo CapobiancoLas Vegas$17K
- Rogelio MachucaLas Vegas$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.